Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CHFSNASDAQ:CTSONASDAQ:MODDNASDAQ:STRR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCHFSNuwellis$0.20-10.6%$4.79$4.86▼$37.50$1.19M1.55467,323 shs2.25 million shsCTSOCytosorbents$1.03-5.5%$1.01$0.71▼$1.61$64.49M1.19149,288 shs118,178 shsMODDModular Medical$0.73-0.2%$0.87$0.63▼$2.65$39.53M0.17220,083 shs67,478 shsSTRRStar Equity$1.95-0.5%$2.14$1.72▼$5.35$6.26M0.9316,915 shs6,437 shs20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCHFSNuwellis0.00%-17.42%-67.95%-79.55%-95.12%CTSOCytosorbents0.00%-15.45%-1.89%+5.00%+14.42%MODDModular Medical0.00%+7.38%-13.63%-8.88%-51.07%STRRStar Equity0.00%-3.47%-8.45%-2.01%-51.25%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCHFSNuwellisN/AN/AN/AN/AN/AN/AN/AN/ACTSOCytosorbents1.952 of 5 stars3.52.00.00.02.30.00.6MODDModular MedicalN/AN/AN/AN/AN/AN/AN/AN/ASTRRStar Equity3.5957 of 5 stars3.55.00.00.00.01.71.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCHFSNuwellis 0.00N/AN/AN/ACTSOCytosorbents 3.00Buy$5.50433.98% UpsideMODDModular Medical 0.00N/AN/AN/ASTRRStar Equity 3.00Buy$5.00156.41% UpsideCurrent Analyst Ratings BreakdownLatest STRR, CHFS, CTSO, and MODD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/25/2025CTSOCytosorbentsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.005/15/2025CTSOCytosorbentsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.005/15/2025CTSOCytosorbentsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$1.00 ➝ $1.005/15/2025STRRStar EquityMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$8.00 ➝ $5.005/2/2025CTSOCytosorbentsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00(Data available from 7/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCHFSNuwellis$5.51M0.22N/AN/A$12.79 per share0.02CTSOCytosorbents$35.60M1.81N/AN/A$0.20 per share5.15MODDModular MedicalN/AN/AN/AN/A$0.42 per shareN/ASTRRStar Equity$53.36M0.12$0.32 per share6.01$10.98 per share0.18Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCHFSNuwellis-$18.11M-$279.28N/AN/AN/A-254.26%-173.61%-131.01%N/ACTSOCytosorbents-$20.72M-$0.28N/AN/AN/A-41.77%-105.04%-29.18%8/12/2025 (Estimated)MODDModular Medical-$18.82M-$0.51N/A∞N/AN/A-178.13%-151.42%8/12/2025 (Estimated)STRRStar Equity-$10.44M-$3.43N/AN/AN/A-16.43%-8.24%-3.48%8/12/2025 (Estimated)Latest STRR, CHFS, CTSO, and MODD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/20/2025Q4 2025MODDModular Medical-$0.11-$0.12-$0.01-$0.12N/AN/A5/14/2025Q1 2025CTSOCytosorbents-$0.08-$0.06+$0.02-$0.02$9.01 million$8.73 million5/14/2025Q1 2025STRRStar Equity-$0.25-$0.52-$0.27-$0.37$16.35 million$12.92 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCHFSNuwellisN/AN/AN/AN/AN/ACTSOCytosorbentsN/AN/AN/AN/AN/AMODDModular MedicalN/AN/AN/AN/AN/ASTRRStar EquityN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCHFSNuwellisN/A6.875.97CTSOCytosorbents0.982.612.30MODDModular MedicalN/A10.6910.69STRRStar Equity0.221.420.88Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCHFSNuwellis65.06%CTSOCytosorbents32.87%MODDModular Medical27.47%STRRStar Equity3.84%Insider OwnershipCompanyInsider OwnershipCHFSNuwellis0.60%CTSOCytosorbents6.60%MODDModular Medical20.46%STRRStar Equity33.51%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCHFSNuwellis666.04 millionN/ANot OptionableCTSOCytosorbents22062.61 million58.48 millionOptionableMODDModular Medical2054.25 million43.15 millionNot OptionableSTRRStar Equity4603.21 million2.13 millionNot OptionableSTRR, CHFS, CTSO, and MODD HeadlinesRecent News About These CompaniesSTAR EQUITY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Star Equity ...May 24, 2025 | morningstar.comM$HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of Star Equity Holdings, Inc. (NASDAQ: STRR)May 24, 2025 | financialpost.comF$HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of Star Equity Holdings, Inc. (NASDAQ: STRR)May 24, 2025 | financialpost.comF$HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of Star Equity Holdings, Inc. (NASDAQ: STRR)May 24, 2025 | globenewswire.comSTAR EQUITY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Star Equity Holdings, Inc. - STRRMay 22, 2025 | businesswire.comStar Equity Holdings, Inc. Declares Cash Dividend of $0.25 for Preferred StockholdersMay 22, 2025 | nasdaq.comHudson Global, Inc.: Star Equity Holdings and Hudson Global Sign Definitive Merger AgreementMay 22, 2025 | finanznachrichten.deSTRR Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Star Equity Holdings, Inc. Is Fair to ShareholdersMay 21, 2025 | businesswire.comStar Equity Holdings, Inc. and Hudson Global, Inc. Announce Definitive Merger Agreement to Form NewCoMay 21, 2025 | quiverquant.comQStar Equity Holdings, Inc. and Hudson Global, Inc. Announce Merger Agreement to Form NewCoMay 21, 2025 | quiverquant.comQStar Equity Holdings and Hudson Global Sign Definitive Merger AgreementMay 21, 2025 | globenewswire.comStar Equity Holdings Declares Cash Dividend for Preferred StockMay 20, 2025 | tipranks.comStar Equity Holdings, Inc. Declares Cash Dividend of $0.25 Per Share of 10% Series A Cumulative Perpetual Preferred StockMay 20, 2025 | globenewswire.comStar Equity signals record $27.9M backlog while advancing Energy Services integrationMay 15, 2025 | msn.comStar Equity Holdings Inc (STRR) Q1 2025: Everything You Need To Know Ahead Of EarningsMay 15, 2025 | finance.yahoo.comStar Equity Holdings, Inc. (NASDAQ:STRR) Q1 2025 Earnings Call TranscriptMay 15, 2025 | insidermonkey.comStar Equity Holdings, Inc. (STRR) Q1 2025 Earnings Call TranscriptMay 14, 2025 | seekingalpha.comStar Equity (STRR) Reports Q1 Loss, Misses Revenue EstimatesMay 14, 2025 | zacks.comStar Equity Holdings, Inc. Announces 2025 First Quarter Financial Results | STRR Stock NewsMay 14, 2025 | gurufocus.comStar Equity Holdings, Inc. Announces 2025 First Quarter Financial ResultsMay 14, 2025 | gurufocus.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSTRR, CHFS, CTSO, and MODD Company DescriptionsNuwellis NASDAQ:CHFSNuwellis, Inc. operates as a medical device company. It engages in the provision of products for the treatment of fluid overload. The firm's products include Aquadex FlexFlow System, which provides an ultrafiltration for the removal of salt and water in patients with hypervolemia, or fluid overload. It operates through Cardiac and Coronary Disease Products segment. The company was founded by Crispin Marsh and William S. Peters in November 1999 and is headquartered in Eden Prairie, MN.Cytosorbents NASDAQ:CTSO$1.03 -0.06 (-5.50%) As of 04:00 PM EasternCytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it develops BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove drugs and chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.Modular Medical NASDAQ:MODD$0.73 0.00 (-0.22%) As of 04:00 PM EasternModular Medical, Inc. operates as a medical device company. It focuses on the design, development, and commercialization of insulin pumps. It offers MODD1, a two-part patch pump for type-1 and type-2 diabetes. The company is headquartered in San Diego, California.Star Equity NASDAQ:STRR$1.95 -0.01 (-0.51%) As of 03:43 PM EasternStar Equity Holdings, Inc. engages in the construction business in the United States and internationally. It operates through two segments: Construction, and Investments. It manufactures modular housing units, structural wall panels, permanent wood foundation systems, and other engineered wood products; supplies general contractors with building materials; holds real estate assets; and manages investments. The company was formerly known as Digirad Corporation and changed its name to Star Equity Holdings, Inc. in December 2020. Star Equity Holdings, Inc. was founded in 1985 and is headquartered in Old Greenwich, Connecticut. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Micron Insiders Sell But Investors Should Buy, Buy, Buy Could Dutch Bros Dethrone Starbucks? Why Investors Are Perking Up ExxonMobil: Limited Risk and Lots of Reward With This Oil Play D-Wave Is Rising Again Despite Dilution—What’s the Deal? Datadog Joins S&P 500, Triggering a New Wave of Upside MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
